Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-31

Study Completion Date

2016-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single center, randomized, placebo-controlled, double-blind trial to assess the safety and immunogenicity of PfSPZ Vaccine administered by direct venous inoculation (DVI).

The study to be conducted in Baney District, Bioko Island, Equatorial Guinea (EG), will be to establish whether three doses of the higher regimen - three doses of 2.7x10\^5 PfSPZ of the PfSPZ Vaccine administered at 8 week intervals - is as well-tolerated and efficacious in malaria exposed African adults as the five dose regimens. Specifically, the trial will address the following objectives: is the three dose regimen:

1. Safe and well tolerated in Equatoguinean (EG) adults.
2. As immunogenic in EG adults as is the five-dose regimen of 1.35x10\^5 PfSPZ in Tanzanian and U.S. adults or as three-, four- and five-dose regimens of 2.7x10\^5 PfSPZ being tested in Tanzanian, Malian and U.S. adults.

In addition, as an exploratory objective, the volunteers in the EG trial will be followed longitudinally to measure the incidence of malaria during the initial six months following immunization, providing a preliminary assessment of efficacy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.

NCT02859350

Malaria

COMPLETED PHASE1

Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants

NCT02613520

Malaria

COMPLETED PHASE1

Regimen Optimization Trial of PfSPZ Vaccine in Equatorial Guinea

NCT03590340

Malaria

COMPLETED PHASE1

A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses

NCT02215707

Malaria

COMPLETED PHASE1

Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults

NCT03420053

Malaria Malaria,Falciparum

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single center, Phase 1, randomized, double-blind, placebo-controlled trial. Thirty-three healthy male volunteers, aged 18 to 35 years will be recruited into three groups. The first group will be comprised of 3 volunteers who will be vaccinated first before the rest for demonstration of safety. The safety volunteers will receive 2 escalating doses of PfSPZ vaccine at a two week interval, 1.35x10\^5 and 2.7x10\^5 PfSPZ. The second group of 14 - 20 volunteers will receive three vaccinations of 2.7x10\^5 PfSPZ that will be given at 0, 8 and 16 weeks (in the Tanzania trial, volunteers will receive a five dose regimen at 0, 4, 8, 12 and 18 weeks). The third group of 7 - 10 volunteers will act as control group for group 2 and will receive three injections of normal saline at 0, 8 and 16 weeks respectively.

Volunteers in groups 2 and 3 will only be injected when the Safety Monitoring Committee (SMC) provides clearance based on the results from the sentinel 3 volunteers (group 1). For groups 2 and 3, five volunteers will be vaccinated with the first dose before the remaining volunteers are vaccinated on a subsequent day.

The control volunteers will help better assess the occurrence of adverse events compared to background disease patterns that occur in this tropical area. The decision to dose escalate in group 1 and to immunize a larger number of volunteers in group 2 in Bioko will be made with full knowledge of all safety data generated in other ongoing trials where the PfSPZ Vaccine is being tested.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malaria Plasmodium Falciparum

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1 (pilot group)

Group 1 will be comprised of 3 volunteers who will be vaccinated first before the rest for demonstration of safety. The safety volunteers will receive 2 escalating doses of PfSPZ vaccine at a two week interval, 1.35x10\^5 and 2.7x10\^5 PfSPZ.

Group Type EXPERIMENTAL

PfSPZ Vaccine

Intervention Type BIOLOGICAL

Aseptic, purified, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites vaccine

Group 2

The second group of 14 - 20 volunteers will receive three vaccinations of 2.7x10\^5 PfSPZ Vaccine that will be given at 0, 8 and 16 weeks

Group Type EXPERIMENTAL

PfSPZ Vaccine

Intervention Type BIOLOGICAL

Aseptic, purified, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites vaccine

Group 3

The third group of 7 - 10 volunteers will act as control group for group 2 and will receive three injections of normal saline at 0, 8 and 16 weeks respectively.

Group Type PLACEBO_COMPARATOR

Normal Saline

Intervention Type OTHER

0.9% Sodium chloride solution for injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PfSPZ Vaccine

Aseptic, purified, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites vaccine

Intervention Type BIOLOGICAL

Normal Saline

0.9% Sodium chloride solution for injection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy literate male aged between 18 - 35 years
* Good health status based on history and clinical examination.
* Long term (at least two year) or permanent residence in the city of Baney or community of Rebola, Bioko Island, Equatorial Guinea
* Free from malaria parasitaemia by blood smear at screening
* Not suffering from any chronic illness including HIV/AIDS.
* Able and willing to come for complete one year follow up.
* Answered correctly 10 out 10 questions demonstrating their understanding of study and study procedures.
* Written informed consent.
* Volunteer agrees to inform study doctor and agrees to release medical information concerning contra-indications for participation in the study.
* Living with a third party who will contact the study team, if there is any alteration of consciousness during the first six months of the study.
* Willingness to be attended by a study clinician and take all necessary medications prescribed during study period.
* Availability through mobile phone 24 hours during the whole study period.
* Agreement not to participate in another study during the study period.
* Agreement not to donate blood during the study period.
* Willingness to attend all study visits.
* Willingness to undergo HIV, hepatitis B and hepatitis C tests.

Exclusion Criteria

* Plans to travel outside the Bioko, Equatorial Guinea in first nine months of the study.
* Previous receipt of an investigational malaria vaccine or participation in a malaria drug study.
* History of arrhythmias or prolonged QT-interval or other cardiac disease.
* History of drug or alcohol abuse interfering with normal social function.
* A history of psychiatric disease.
* The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying drugs within three months of study onset (inhaled and topical corticosteroids are allowed) and during the study period.
* Symptoms, physical signs and laboratory values suggestive of systemic disorders including renal, hepatic, blood, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, and other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers.
* History of diabetes mellitus or cancer.
* An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system.
* Clinically significant abnormalities in electrocardiogram (ECG) at screening.
* Body Mass Index (BMI) below 18 or above 30 kg/m2.
* Any clinically significant deviation from the normal range in biochemistry or hematology blood tests or in urine analysis or electrolytes.
* Positive HIV, hepatitis B virus or hepatitis C virus tests.
* Participation in any other clinical study within 30 days prior to the onset of the study or during the study period.
* Volunteers unable to be closely followed for social, geographic or psychological reasons.
* Study team employees and their immediate family relatives.
* Any confirmed or suspected immunosuppressive or immunodeficient condition, including asplenia.
* Risk factor for clinically active tuberculosis + positive tuberculin skin test (TST)

Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes